PRESS RELEASE published on 04/27/2023 at 07:30, 3 years 1 month ago Formycon publishes results for financial year 2022
PRESS RELEASE published on 04/25/2023 at 07:00, 3 years 1 month ago Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
PRESS RELEASE published on 02/07/2023 at 07:30, 3 years 4 months ago Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
PRESS RELEASE published on 02/06/2023 at 07:30, 3 years 4 months ago Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
PRESS RELEASE published on 02/02/2023 at 08:00, 3 years 4 months ago Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/02/2023 at 07:30, 3 years 4 months ago EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
PRESS RELEASE published on 02/01/2023 at 23:30, 3 years 4 months ago EQS-Adhoc: Formycon AG upsizes capital increase from authorized capital following strong demand
PRESS RELEASE published on 02/01/2023 at 17:40, 3 years 4 months ago EQS-Adhoc: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/01/2023 at 17:40, 3 years 4 months ago EQS-Adhoc: Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
PRESS RELEASE published on 01/09/2023 at 13:05, 3 years 5 months ago EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
Published on 06/20/2026 at 01:00, 11 hours 7 minutes ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 12 hours 7 minutes ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 7 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 10 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 11 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 06:00, 6 hours 7 minutes ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 15 hours 49 minutes ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 17 hours 5 minutes ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 18:00, 18 hours 7 minutes ago Successful issue of a CHF 100 million green bond
Published on 06/19/2026 at 19:33, 16 hours 34 minutes ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 16 hours 43 minutes ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 1 day 18 hours ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 1 day 18 hours ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 1 day 18 hours ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
